• Sulfo-NHS-Biotin in Single-Cell Translation

  2026-08-31

  A mechanistic and strategic guide to using Sulfo-NHS-Biotin for controlled protein and cell-surface labeling, with a translational framework inspired by capped nanovials and scalable single-cell assays.

• GSH and GSSG Assay Kit for Hypoxic TME

  2026-08-31

  Turn hypoxia and immunometabolism experiments into actionable redox data with paired total glutathione and GSSG measurements. This workflow shows how to preserve samples, separate GSH from GSSG, compare tumor and immune compartments, and troubleshoot matrix-driven assay variability.

• NAD+ Workflows for Stress and Autophagy Assays

  2026-08-30

  Use NAD+ to connect redox state, enzymatic activity, and stress adaptation without treating a metabolic readout as proof of autophagy. This workflow pairs NAD+ measurements with caspase, PARP1, LC3B, ATG7, and H2AX endpoints to improve mechanistic resolution in breast cancer cell models.

• Angiotensin (1-7) Research Workflows

  2026-08-29

  Build reproducible Angiotensin (1-7) assays around Mas receptor biology, peptide stability, and experimentally defined dosing. This guide connects cell, biochemical, and disease-model workflows with practical controls for studying anti-fibrotic, anti-inflammatory, metabolic, and neuroprotective effects.

• Salmonella Targets FAM134B to Block ER-Phagy

  2026-08-28

  A 2025 Nature Communications study identifies the ER-phagy receptor FAM134B as a host defense target manipulated by Salmonella Typhimurium. The work links SopF-dependent disruption of FAM134B oligomerization to reduced ER-phagy, higher intracellular bacterial burden, and more severe disease in FAM134B-deficient mice.

• Honokiol Workflows for NF-κB and T-Cell Assays

  2026-08-28

  Honokiol enables coordinated investigation of NF-κB signaling, oxidative stress, and immune-cell metabolism in cancer and inflammation models. This practical workflow pairs dose-controlled small-molecule perturbation with PKM splicing, ROS, viability, and antitumor-immunity readouts.

• Clarithromycin CYP3A Inhibition Workflows

  2026-08-27

  Build controlled CYP3A inhibition assays for drug-drug interaction research, statin metabolism interaction studies, and translational pharmacokinetics. This workflow combines solvent control, pathway-specific comparators, analytical QC, and troubleshooting for more interpretable results.

• Engineered Esophagus: Large-Animal Study Insights

  2026-08-27

  This Nature Biotechnology study combines an autologous cell-loaded decellularized scaffold with bioreactor conditioning, biodegradable stenting, and vascularizing pleural coverage to reconstruct a circumferential esophageal segment in growing minipigs. The resulting grafts supported oral feeding, progressive neuromuscular and vascular regeneration, and secondary peristalsis, although survival, sample size, and long-term translation remain important limitations.

• Triiodothyronine (T3) in Beige Adipocyte Research

  2026-08-26

  Use Triiodothyronine as a controlled thyroid-receptor perturbation alongside SEMA3E gain- or loss-of-function experiments to connect transcriptional signaling with thermogenic metabolism. This workflow combines dose-controlled T3 exposure, β-catenin pathway controls, RT-qPCR, immunostaining, and oxygen-consumption measurements for more interpretable beige adipocyte assays.

• QX77 Molecular Chaperone Activator Workflow

  2026-08-26

  QX77 connects LAMP2A-centered chaperone-mediated autophagy with Rab11-dependent trafficking and ES-cell differentiation assays. This practical guide separates CMA effects from mitophagy, translates a recent ETS1 study into assay decisions, and provides fresh-solution handling and troubleshooting strategies.

• NAD+ and Energy-Stress Assay Interpretation

  2026-08-25

  Nicotinamide Adenine Dinucleotide (NAD+) is both a redox coenzyme and a signaling substrate that can reshape how energy-stress and autophagy experiments are interpreted. This article connects NAD+ chemistry with the revised AMPK–ULK1 model and presents a practical framework for separating reagent effects from cellular stress responses.

• EdU Imaging Kits (HF594) and the PNI Question

  2026-08-25

  A translational framework for using EdU-based DNA synthesis measurement to strengthen mechanistic studies of pancreatic ductal adenocarcinoma perineural invasion, with emphasis on Schwann cell plasticity, PGE2 signaling, assay design, and preclinical decision-making.

• Mitoxantrone: Mechanism, ABCG2 Resistance & Research

  2026-08-24

  Mitoxantrone is a DNA-intercalating topoisomerase II inhibitor used as an anticancer research compound. Current evidence also shows that ABCG2 inhibition by marein can increase mitoxantrone sensitivity in resistant cancer-cell models, while product handling requires DMSO, light protection, and frozen storage.

• Trifluoperazine 2HCl: From D2 to Translation

  2026-08-24

  Trifluoperazine 2HCl offers a potent entry point into dopamine D2 receptor biology while opening a disciplined path toward immune and cancer research. This thought-leadership guide connects receptor pharmacology, assay design, metabolic evidence, and translational decision-making without overstating what a D2 inhibitor can prove on its own.

• ZK53 and the Mitochondrial Proteostasis Opportunity

  2026-08-23

  ZK53 is a selective human mitochondrial serine protease ClpP activator that converts mitochondrial proteostasis into a tractable anticancer vulnerability. This thought-leadership perspective connects ClpP activation with electron transport chain disruption, cell-cycle control, ferroptosis sensitization, and translational study design.

8424 records 1/562 page Next 12345 下5页 Last page